Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06283576
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-04-24
First Post:
2024-02-14
Brief Title:
Pancreatic Cancer Initial Detection Via Liquid Biopsy
Sponsor:
Karolinska University Hospital
Organization:
Karolinska University Hospital
Study Overview
Official Title:
Pancreatic Cancer Initial Detection Via Liquid Biopsy
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PANCAID
Brief Summary:
The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer With a set of different liquid biopsy methods it is the aim to measure these markers in well-defined patient cohorts For the entire series of these studies the following groups are planned 1 Histologically proven early-stage pancreatic cancer eg T1ab and T2 carcinomas N0M0 2 Intraductal papillary mucinous neoplasia IPMN that were operated with verification of the benign premalignant or malignant histology 3 ordinary branched-duct IPMN 4 individuals at risk IAR with and without IPMN with and without known hereditary cancer gene eg BRCA2 5 a high risk group of patients with chronic pancreatitis aged 55-65 who are heavy smokers 40 PY with newly onset diabetes mellitus NODM
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None